Trials / Unknown
UnknownNCT03178656
A Trial to Compare Surgery With Sorafenib for Hepatic Celluler Cancer With Portal Vein Tumor Thrombosis
RCT Research: the Treatment of Hepatic Carcinoma With Portal Vein Branch Tumor Thrombosis (Resection or Sorafenib)
- Status
- Unknown
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 54 (estimated)
- Sponsor
- Huazhong University of Science and Technology · Academic / Other
- Sex
- All
- Age
- 20 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
According to the guidelines recommended, only a few new targeted therapy drugs treatment, such as Sorafenib, is proper. It's 3 year survival rate is only 8% or so. According to our previous study, patients with hepatic carcinoma without portal vein tumor thrombus backbone and the contralateral tumor thrombus applyed tumor excision, along with tumor thrombus, the 3 year survival rate can reach 39.9%, the 5-year survival rate can reach 22.7%, curative effect is obviously better.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Sorafenib | continuous application of the drugs |
| PROCEDURE | surgery | curative resection |
Timeline
- Start date
- 2016-12-15
- Primary completion
- 2018-04-15
- Completion
- 2019-12-15
- First posted
- 2017-06-07
- Last updated
- 2017-12-21
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT03178656. Inclusion in this directory is not an endorsement.